ライフサイエンスコーパス: stem cell transplantation

1 g olanzapine in the setting of hematopoietic stem cell transplantation.

2 int inhibitors, and autologous or allogeneic stem cell transplantation.

3 major limitation of allogeneic hematopoietic stem cell transplantation.

4 and mortality after allogeneic hematopoietic stem cell transplantation.

5 ith AML cured after allogeneic hematopoietic stem cell transplantation.

6 st-ET/PV myelofibrosis undergoing allogeneic stem cell transplantation.

7 autologous and even allogeneic hematopoietic stem cell transplantation.

8 ed by autologous or allogeneic hematopoietic stem cell transplantation.

9 chemotherapy in the setting of hematopoietic stem cell transplantation.

10 sful regeneration of vitalized pulp via pulp stem cell transplantation.

11 onal conditioning regimens for hematopoietic stem cell transplantation.

12 ing complication of allogeneic hematopoietic stem cell transplantation.

13 ximab from the early 2000s followed by blood stem cell transplantation.

14 chemotherapy, and 42% of patients underwent stem cell transplantation.

15 atched siblings has been a pivotal change in stem cell transplantation.

16 arable to those of HLA-matched hematopoietic stem cell transplantation.

17 dence of GvHD after allogeneic hematopoietic stem cell transplantation.

18 the nonwhite patients required hematopoietic stem cell transplantation.

19 s, as occurs frequently during hematopoietic stem cell transplantation.

20 ed to high-dose chemotherapy with autologous stem cell transplantation.

21 ative conditioning regimen for hematopoietic stem cell transplantation.

22 mens are increasingly used in haematopoietic stem cell transplantation.

23 ith conditioning chemotherapy and allogeneic stem cell transplantation.

24 matopoietic donor populations at the time of stem cell transplantation.

25 atently infected cells before haematopoietic stem cell transplantation.

26 curative option for CMML remains allogeneic stem cell transplantation.

27 who are potential candidates for autologous stem cell transplantation.

28 ed into intensive strategies with autologous stem cell transplantation.

29 be achievable with allogeneic hematopoietic stem cell transplantation.

30 27-321) days after allogeneic hematopoietic stem cell transplantation.

31 d chemotherapy with or without hematopoietic stem cell transplantation.

32 stitution following allogeneic hematopoietic stem cell transplantation.

33 at affects patients undergoing hematopoietic stem cell transplantation.

34 itive recipients of allogeneic hematopoietic stem cell transplantation.

35 donor-recipient pairs undergoing allogeneic stem cell transplantation.

36 t with high-dose chemotherapy and autologous stem cell transplantation.

37 gic diseases in the context of hematopoietic stem cell transplantation.

38 llergen-specific responses in the context of stem cell transplantation.

39 te graft-versus-myeloma effect of allogeneic stem cell transplantation.

40 llergen-specific responses via hematopoietic stem cell transplantation.

41 d be corrected with allogeneic hematopoietic stem cell transplantation.

42 eutropenia and solid organ and hematopoietic stem cell transplantation.

43 ork in the field of allogeneic hematopoietic stem cell transplantation.

44 ally corrected with allogeneic hematopoietic stem cell transplantation.

45 patients who are not eligible for autologous stem-cell transplantation.

46 Thirteen participants proceeded to stem-cell transplantation.

47 e progression after autologous hematopoietic stem-cell transplantation.

48 utcomes with chemotherapy without undergoing stem-cell transplantation.

49 %; of these patients, 45% went on to undergo stem-cell transplantation.

50 could resume quizartinib after haemopoietic stem-cell transplantation.

51 f complications, and 21 (23%) relapsed after stem-cell transplantation.

52 with salvage chemoimmunotherapy regimens and stem-cell transplantation.

53 le myeloma who are ineligible for autologous stem-cell transplantation.

54 ree survival, primarily following autologous stem-cell transplantation.

55 ith multiple myeloma who were ineligible for stem-cell transplantation.

56 GVHD who had received consecutive allogeneic stem-cell transplantation.

57 is for the routine management of GVHD during stem-cell transplantation.

58 to mortality and morbidity after allogeneic stem-cell transplantation.

59 sed multiple myeloma who were ineligible for stem-cell transplantation.

60 icoid-refractory acute GVHD after allogeneic stem-cell transplantation.

61 lymphoma who were ineligible for autologous stem-cell transplantation.

62 decisions and overall success of allogeneic stem cell transplantations.

63 ved only following allogeneic haematopoietic stem cell transplantation(2,3), may be feasible in rare

64 Forty-six patients received stem cell transplantation (20 autologous, 26 allogeneic)

65 After undergoing stem cell transplantation, 94% of allergen-specific IgE

66 The success of allogeneic hematopoietic stem cell transplantation, a key treatment for many diso

67 lete haploidentical allogeneic hematopoietic stem cell transplantation after a reduced-intensity cond

68 Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume

69 Autologous haematopoietic stem cell transplantation (AHSCT) has been explored as a

70 Autologous hematopoietic stem cell transplantation (AHSCT) with anti-thymocyte gl

71 ota and outcomes in allogeneic hematopoietic stem cell transplantation (allo-HCT) have thus far large

72 g-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their respecti

73 ider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD

74 l responses in some allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, its cl

75 Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was the first succ

76 the wider usage of allogeneic hematopoietic stem cell transplantation (allo-HSCT), which is an effec

77 Allogeneic hematopoietic stem cell transplantation (allo-SCT) offers cure for a v

78 ) will benefit from allogeneic hematopoietic stem-cell transplantation (allo-HSCT).

79 ns for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid l

80 gical malignancies, allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only availab

81 Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important cura

82 -versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT) is characterized by

83 Allogeneic stem cell transplantation (alloSCT) of homozygous CCR5 D

84 yeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave

85 (2020) show that hematopoietic stem cell transplantation, an established therapy, impro

86 ractory disease or relapsed after autologous stem-cell transplantation; an Eastern Cooperative Oncolo

87 received upfront therapy (14 haematopoietic stem cell transplantation and 4 chemotherapy), 4 (15%) p

88 nts (12%) underwent allogeneic hematopoietic stem cell transplantation and 640 (31.0%) were neutropen

89 idney, liver, lung, heart, and hematopoietic stem cell transplantation and argue that there are not o

90 Despite limited progress, stem cell transplantation and donor lymphocyte infusions

91 Hematopoietic stem cell transplantation and gene therapy are the only

92 agnosis, our patient underwent hematopoietic stem cell transplantation and is well 8 years later.

93 Hematopoietic stem cell transplantation and NF-kappaB1 pathway-targete

94 is clinically relevant in both hematopoietic stem cell transplantation and solid organ transplantatio

95 are full donor chimeras after hematopoietic stem cell transplantation and subsequently received kidn

96 -host disease after allogeneic hematopoietic stem cell transplantation and with new onset type 1 diab

97 atients had received high-dose melphalan and stem cell transplantation and/or treatment with a protea

98 duction were allocated to undergo allogeneic stem-cell transplantation and those with low minimal res

99 vances in gene therapy, better outcomes with stem cell transplantation, and discoveries of putative n

100 erlying malignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia were not.

101 herapy followed by autologous haematopoietic stem cell transplantation, and prospective trials have d

102 s are age at diagnosis, age at hematopoietic stem cell transplantation, and the comorbidities that de

103 e end of induction were allocated to undergo stem-cell transplantation, and 82 patients with low mini

104 high minimal residual disease benefited from stem-cell transplantation, and targeted therapies might

105 ditional studies and referral for allogeneic stem cell transplantation are also discussed.

106 cal malignancies or undergoing hematopoietic stem cell transplantation are vulnerable to colonization

107 Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progr

108 we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lena

109 Autologous stem cell transplantation (ASCT) is a standard of care i

110 d dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline t

111 y with high-dose chemotherapy and autologous stem cell transplantation (ASCT) or conventional chemoth

112 Autologous stem cell transplantation (ASCT) remains the standard of

113 hese new agents, peripheral blood autologous stem cell transplantation (ASCT) was the mainstay of the

114 eauville score </=2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive pa

115 diversity plays a key role during allogeneic stem cell transplantation (ASCT), and loss of diversity

116 ed and reinfused after a standard autologous stem cell transplantation (ASCT).

117 on, and patients could proceed to autologous stem cell transplantation (ASCT).

118 lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for pa

119 ot being considered for immediate autologous stem-cell transplantation (ASCT).

120 (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT).

121 mucositis (OM) is a frequent complication of stem cell transplantation-associated toxicity in haemato

122 rs of age undergoing allogenic hematopoietic stem cell transplantation at our institution.

123 (IIV) schedules in autologous haematopoietic stem cell transplantation (autoHCT) patients.

124 e for high-dose chemotherapy with autologous stem-cell transplantation, because of their age (>=65 ye

125 erally treated with allogeneic hematopoietic stem cell transplantation, but alternatives are needed f

126 CB) has had considerable impact in pediatric stem cell transplantation, but its wider use is limited

127 atients with multiple myeloma ineligible for stem-cell transplantation, but further external validati

128 We sought to improve hematopoietic stem cell transplantation by developing a new mobilizati

129 roximately one-fifth of patients, autologous stem cell transplantation can be considered up front or

130 Stem cell transplantation can improve behavioral recover

131 e various empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, an

132 oid leukaemia (two [3%]), and haematopoietic stem-cell transplantation complications (five [7%]).

133 ience acute toxicity during prehematopoietic stem cell transplantation conditioning.

134 n both models were history of haematopoietic stem-cell transplantation, cumulative alkylating drug do

135 lications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic tech

136 n-diagnostic purposes such as haematopoietic stem cell transplantation donor screening or population

137 bined approach of alphabetaTCR-CD19-depleted stem cell transplantation, enabling immunosuppression-fr

138 nts undergoing chemotherapy or hematopoietic stem cell transplantation for hematological malignancy a

139 of children require allogeneic hematopoietic stem cell transplantation for long-term leukemia-free su

140 ovide proof of principle for the benefits of stem cell transplantation for other fatal leukodystrophi

141 ineural deafness that requires hematopoietic stem cell transplantation for survival.

142 sis and the curative effect of hematopoietic stem cell transplantation for the hematopoietic features

143 ing lymphocytes, and allogeneic haemopoietic stem-cell transplantation for cancer treatment.

144 Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined i

145 continuous-infusion reinduction followed by stem cell transplantation forms the basis for testing ne

146 In the patients allocated to undergo stem-cell transplantation, four relapses and three death

147 nctional cure after allogeneic hematopoietic stem cell transplantation from a donor carrying a mutati

148 f renal transplantations after hematopoietic stem cell transplantation from the same donor and compar

149 observed after haploidentical hematopoietic stem cell transplantation (h-HSCT) with posttransplant c

150 Bone marrow stem cell transplantation had not been accessible during

151 -dose chemotherapy and subsequent autologous stem-cell transplantation, had an Eastern Cooperative On

152 or B-cell reconstitution after hematopoietic stem cell transplantation has been observed, we hypothes

153 me inhibitors, and autologous haematopoietic stem-cell transplantation has improved outcomes for pati

154 CHIP's implications for stem cell transplantation have been harder to identify d

155 nd-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis.

156 l lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few tre

157 ge B-cell lymphoma ineligible for autologous stem-cell transplantation having a complete response, an

158 Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute mye

159 High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of

160 fection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major cause of tr

161 Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal

162 of stem cells to use in early haematopoietic stem cell transplantation (HSCT) approaches for several

163 rly recognized complication of hematopoietic stem cell transplantation (HSCT) associated with excessi

164 ither autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 w

165 derwent their first allogeneic hematopoietic stem cell transplantation (HSCT) between Jan 3, 2001, an

166 deletion status, and whether haematopoietic stem cell transplantation (HSCT) had been done, as well

167 ion on clinical outcomes after hematopoietic stem cell transplantation (HSCT) has been studied, littl

168 cellular engraftment following haemopoietic stem cell transplantation (HSCT) has historically been l

169 Hematopoietic stem cell transplantation (HSCT) improves clinical outco

170 erapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) in autoinflammatory dis

171 tegies, matched sibling donor haematopoietic stem cell transplantation (HSCT) in children (offering a

172 cent findings strongly support hematopoietic stem cell transplantation (HSCT) in patients with severe

173 iation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients w

174 outcomes following allogeneic haematopoietic stem cell transplantation (HSCT) in two patients with AL

175 Allogeneic hematopoietic stem cell transplantation (HSCT) is a critically importa

176 Hematopoietic stem cell transplantation (HSCT) is a curative therapy f

177 Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment

178 tive regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical nee

179 ed, unrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associated with cons

180 biology beyond 3 months after hematopoietic stem cell transplantation (HSCT) is complex.

181 linical management, allogeneic hematopoietic stem cell transplantation (HSCT) is still hampered by hi

182 f metabolism (IEM), allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure.

183 Presymptomatic hematopoietic stem cell transplantation (HSCT) is the only treatment f

184 apse and mortality in the post-hematopoietic stem cell transplantation (HSCT) period, IFDs, especiall

185 Hematopoietic stem cell transplantation (HSCT) represents a potentiall

186 donor is available, allogeneic hematopoietic stem cell transplantation (HSCT) should be pursued.

187 Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD And

188 ents relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) using donor-derived CD1

189 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored.

190 Hematopoietic stem cell transplantation (HSCT) was used as consolidati

191 y, we compared the outcomes of hematopoietic stem cell transplantation (HSCT) with TCRalphabeta+/CD19

192 ons to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing numb

193 d with conventional therapy or hematopoietic stem cell transplantation (HSCT), and that the poor PROs

194 ing complication of allogeneic hematopoietic stem cell transplantation (HSCT), posing as a significan

195 posed for potentially curative hematopoietic stem cell transplantation (HSCT), the donor being her ha

196 ed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT).

197 s complication post allogeneic hematopoietic stem cell transplantation (HSCT).

198 the only curative treatment is hematopoietic stem cell transplantation (HSCT).

199 tment failure after allogeneic hematopoietic stem cell transplantation (HSCT).

200 s a complication of allogeneic hematopoietic stem cell transplantation (HSCT).

201 of morbidity and mortality in hematopoietic stem cell transplantation (HSCT).

202 and in pediatric recipients of hematopoietic stem cell transplantation (HSCT).

203 arrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with

204 f mobilisation and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisat

205 ukemia (B-ALL) fare poorly and hematopoietic stem-cell transplantation (HSCT) is often pursued in fir

206 ent'-underwent two allogeneic haematopoietic stem-cell transplantation (HSCT) procedures using a dono

207 t before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus b

208 tment, including and excluding hematopoietic stem-cell transplantation (HSCT).

209 t occurs in children undergoing haemopoietic stem-cell transplantation (HSCT).

210 eloablative 10/10 HLA-matched haematopoietic stem-cell transplantation (HSCT).

211 of idarubicin and cytarabine, or allogeneic stem cell transplantation if eligible.

212 D-VTd before and after autologous stem-cell transplantation improved depth of response and

213 outine infectious disease screening prior to stem cell transplantation in a 16-year-old female with B

214 ritical for the development of hematopoietic stem cell transplantation in alpha- and beta- mannosidos

215 ed complications of allogeneic hematopoietic stem cell transplantation in children.

216 as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lympho

217 may be possible, for example, haematopoietic stem cell transplantation in FA and NBS, future early in

218 ne marrow ablation followed by hematopoietic stem cell transplantation in multiple myeloma and acute

219 mmune reconstitution following hematopoietic stem cell transplantation in NIK deficiency.

220 Finally, hematopoietic stem cell transplantation in patients reduces globoid ce

221 (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (six of 11) of

222 Allogeneic stem cell transplantation is a cornerstone of curative t

223 Hematopoietic stem cell transplantation is a potential curative therap

224 Bone marrow stem cell transplantation is a potentially curative trea

225 Mismatched stem cell transplantation is associated with a high risk

226 Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis,

227 Overall survival following allogeneic stem cell transplantation is improving with substantial

228 ely affected patients for whom hematopoietic stem cell transplantation is not available.

229 HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonl

230 Allogeneic hematopoietic stem cell transplantation is the only available cure.

231 Hematopoietic stem cell transplantation is the only curative option, b

232 Allogeneic hematopoietic stem cell transplantation is the only potentially curati

233 At present, hematopoietic stem cell transplantation is the therapy of choice for p

234 ide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europ

235 loma (MM) relapsing after a prior autologous stem-cell transplantation leads to increased remission d

236 Limbal stem cell transplantation (LSCT) and Boston keratoprosth

237 those with multiple relapses, hematopoietic stem cell transplantation may be considered, but its eff

238 transfusions and hydroxycarbamide, although stem cell transplantation might be a potentially curativ

239 lleagues asked whether the results of neural stem cell transplantation might be improved by accommoda

240 Whether matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) can reduce velociti

241 HD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a respo

242 rophy treated with allogeneic haematopoietic stem cell transplantation on a compassionate basis in fo

243 s can be made on the impact of hematopoietic stem cell transplantation on allergy transfer or cure of

244 Despite successful hematopoietic stem cell transplantation, ongoing progression of gastro

245 oor, particularly in patients ineligible for stem cell transplantation or who fail induction therapy

246 until 1 year after allogeneic hematopoietic stem-cell transplantation or until 1 year after the last

247 ot be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs

248 , chemorefractory, relapsed after allogeneic stem-cell transplantation, or were otherwise ineligible

249 aluated 1,974 adult allogeneic hematopoietic stem cell transplantation patients from Beth Israel Deac

250 ective analysis of 192 autologous peripheral stem cell transplantation patients with lymphoma and mul

251 al immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses.

252 Hematopoietic stem cell transplantation profoundly reduces allergen-sp

253 ed at a median of 8.6 years after allogeneic stem cell transplantation (range, 2-23 y) with a median

254 ssociated with solid organ and hematopoietic stem cell transplantation, rapid and accurate microbiolo

255 Among them, allogeneic hematopoietic stem cell transplantation remains the only potentially c

256 -SIGN (rs11465384 and rs7248637), allogeneic stem cell transplantation, respiratory virus infection,

257 Salvage autologous stem-cell transplantation (sASCT) in patients with multi

258 on by allogeneic or autologous hematopoietic stem cell transplantation (SCT) and vinblastine monother

259 ion is a major complication after allogeneic stem cell transplantation (SCT).

260 igned to receive single or tandem autologous stem-cell transplantation (SCT) after induction chemothe

261 , such as anti-CD20 monoclonal antibodies or stem-cell transplantation, should receive antiviral prop

262 Spermatogonial stem cell transplantation (SSCT) is an experimental tech

263 ting novel targeted therapies and autologous stem cell transplantation strategies.

264 sed multiple myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NC

265 Haematopoietic stem cell transplantation, the oral formulation cladribi

266 oses chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients

267 dose chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients

268 e myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progressi

269 lication of an optochemogenetics approach in stem cell transplantation therapy after stroke for optim

270 e therapeutic options and pushing allogeneic stem cell transplantation to a third-line treatment of m

271 ells (hNPCs) are a promising cell source for stem cell transplantation to treat neurological diseases

272 xtended the curative potential of allogeneic stem-cell transplantation to older adults with high-risk

273 e myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus le

274 lymphoproliferative disorders, hematopoietic stem cell transplantation, treatment with steroids or ot

275 The success of allogeneic stem cell transplantation underscores the immunoresponsi

276 1 mutations in instances in which allogeneic stem cell transplantation using a related donor is envis

277 Corneal limbal epithelial stem cell transplantation using cultivated human corneal

278 HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophos

279 lete haploidentical allogeneic hematopoietic stem cell transplantation using posttransplant cyclophos

280 ain individual IgE responses to allergens by stem cell transplantation was 1.7% and 2.3%, respectivel

281 time for PED development after hematopoietic stem cell transplantation was approximately 24 months.

282 MV-infection in patients after hematopoietic stem cell transplantation was initiated.

283 Hurler's syndrome treated with hematopoietic stem cell transplantation was referred for decreased vis

284 cer associated with allogeneic hematopoietic stem cell transplantation, we evaluated 1,974 adult allo

285 or were otherwise ineligible for allogeneic stem-cell transplantation were enrolled.

286 after or were not candidates for autologous stem-cell transplantation were enrolled.

287 rapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; p

288 ul, especially in the context of bone marrow stem cell transplantation where early rejection of immun

289 utcomes compared with chemoimmunotherapy and stem-cell transplantation, which are uncertain.

290 Rescue strategies may include stem-cell transplantation, which remains the only curati

291 eutropenic patients undergoing hematopoietic stem cell transplantation, who receive multiple courses

292 malignancies after allogeneic hematopoietic stem cell transplantation will develop the pleomorphic a

293 efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosp

294 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not expres

295 oietic stem and progenitor cells (HSPCs) for stem cell transplantation, with a five-day course of gra

296 children following allogeneic hematopoietic stem cell transplantation, with adoptive transfer of ade

297 ieved a response and proceeded to allogeneic stem cell transplantation, with grade 3-4 graft-versus-h

298 vived at least 6 months following allogeneic stem cell transplantation without steroid-refractory acu

299 Hematopoietic stem cell transplantation would result in normal B-cell

300 ratumumab to VTd before and after autologous stem-cell transplantation would improve stringent comple